Please assess the completion status of the following clinical trial:

Trial Title: External Beam Radiation With Intratumoral Injection of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Intermediate or high grade sarcoma as determined by pathology review~* Musculoskeletal tumor in extremities, trunk or chest wall.~* Primary tumor or isolated locally recurrent tumor greater than 5 cm in diameter.~* Clinical Stage T2N0M0 (AJCC 6th edition)~* Patient is not a candidate for neoadjuvant chemotherapy.~* Performance status Eastern Cooperative Oncology Group (ECOG) 0 or 1.~* No steroid therapy within 4 weeks of first dendritic cell administration.~* No coagulation disorder.~* Patient's written informed consent.~* No contraindication to resection.~* Adequate organ function (measured within a week of beginning treatment).~  * White blood count (WBC) \> 3,000/mm to the third power and absolute neutrophil count (ANC) \>1500/mm to the third power~ * Platelets \> 100,000/mm to the third power~ * Hematocrit \> 25%~ * Bilirubin \< 2.0 mg/dL~ * Creatinine \< 2.0 mg/dL, or creatinine clearance \> 60 mL/min~* Radiation Oncologist must confirm that a 2-3 cm strip of skin can be spared from radiation.~Exclusion Criteria:~* Retroperitoneal location.~* Gastrointestinal stromal tumor (GIST).~* Demonstrated metastatic disease.~* Prior radiation therapy if the current tumor is locally recurrent after prior resection.~* Concurrent treatment with any anticancer agent other than radiation as dictated by the protocol.~* Bleeding disorder.~* H.I.V. infection or other primary immunodeficiency disorder.~* Ongoing systemic therapy with immunosuppressant drugs (e.g. corticosteroids, azathioprine, cyclosporin, methotrexate).~* Any serious ongoing infection.~* Pregnant or lactating women -- Patients in reproductive age must agree to use contraceptive methods for the duration of the study (a pregnancy test will be obtained before treatment).~* ECOG performance status of 2, 3 or 4.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EBRT + DC Injection + Resection (Type: EXPERIMENTAL): Single Arm: EBRT + DC Injection + Resection. Prior to the fourth DC Injection, participants were assigned to 3 cohorts as outlined in that intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).